These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36900151)

  • 1. Challenges of Anti-Mesothelin CAR-T-Cell Therapy.
    Zhai X; Mao L; Wu M; Liu J; Yu S
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin-targeted CAR-T cell therapy for solid tumors.
    Klampatsa A; Dimou V; Albelda SM
    Expert Opin Biol Ther; 2021 Apr; 21(4):473-486. PubMed ID: 33176519
    [No Abstract]   [Full Text] [Related]  

  • 3. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
    Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
    Ding J; Guyette S; Schrand B; Geirut J; Horton H; Guo G; Delgoffe G; Menk A; Baeuerle PA; Hofmeister R; Tighe R
    Oncoimmunology; 2023; 12(1):2182058. PubMed ID: 36875551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
    Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
    Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
    Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment.
    Chen Q; Sun Y; Li H
    Discov Oncol; 2024 Jul; 15(1):289. PubMed ID: 39023820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
    Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma.
    Castelletti L; Yeo D; van Zandwijk N; Rasko JEJ
    Biomark Res; 2021 Feb; 9(1):11. PubMed ID: 33588928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
    Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
    Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
    Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
    Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
    Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.
    El-Serafi I; Micallef Nilsson I; Moter A; Duan Z; Mattsson J; Magalhaes I
    Cancer Immunol Immunother; 2024 Jul; 73(9):163. PubMed ID: 38954005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
    Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
    Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors
    Ye L; Lou Y; Lu L; Fan X
    Exp Ther Med; 2019 Jan; 17(1):739-747. PubMed ID: 30651858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models.
    Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
    J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.
    Haas AR; Golden RJ; Litzky LA; Engels B; Zhao L; Xu F; Taraszka JA; Ramones M; Granda B; Chang WJ; Jadlowsky J; Shea KM; Runkle A; Chew A; Dowd E; Gonzalez V; Chen F; Liu X; Fang C; Jiang S; Davis MM; Sheppard NC; Zhao Y; Fraietta JA; Lacey SF; Plesa G; Melenhorst JJ; Mansfield K; Brogdon JL; Young RM; Albelda SM; June CH; Tanyi JL
    Mol Ther; 2023 Aug; 31(8):2309-2325. PubMed ID: 37312454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.